ConcertoCare is a technology company.
ConcertoCare has raised $140.0M across 2 funding rounds.
ConcertoCare has raised $140.0M in total across 2 funding rounds.
ConcertoCare is a tech-enabled healthcare company that delivers integrated, in-home care to seniors and adults with complex medical and social needs, primarily Medicare, Medicare Advantage, and Medicare+Medicaid beneficiaries.[1][2][3][6] It serves patients across eight U.S. states through interdisciplinary teams of physicians, nurse practitioners, pharmacists, social workers, and health coaches, using its proprietary Patient3D platform for personalized care plans, remote monitoring, and analytics to manage chronic conditions, reduce hospitalizations, and address social determinants like housing and food access.[1][3][4][6] The model has demonstrated strong outcomes, including 47% fewer hospital admissions, 40% fewer readmissions, and 16% fewer ER visits, while boosting wellness visits by 38%, with $132M in revenue as of recent data.[1][2]
ConcertoCare partners with patients' existing primary care providers (PCPs) or offers primary care directly, providing services at no extra cost via insurance plans, including palliative care, behavioral health, telehealth, and caregiver support.[3][6] Its growth includes substantial equity funding and expansion, though it divested PACE programs in California to InnovAge in December 2023.[2]
Founded in 2015 and headquartered in New York, New York, ConcertoCare emerged to tackle barriers faced by older adults with complex conditions, such as heart failure or diabetes, who struggle with traditional healthcare access.[1][3] Julian Harris, MD, serves as Chairman and CEO, bringing expertise from his role as an Operating Partner at Deerfield Management; the company originated as a Cure Collaboration Residency initiative, emphasizing multidisciplinary, in-home support for Medicare+Medicaid and Medicare Advantage patients.[3][5] Early focus centered on "meeting patients where they're at" through CarePartners extending PCP services, backed by technology for analytics and virtual care, quickly gaining traction in five states (and expanding to eight) by coordinating medical, behavioral, and social services.[1][3][6] Pivotal moments include proven clinical results and Deerfield's investment support, positioning it as a leader in risk-bearing care models.[2][5]
ConcertoCare stands out in senior care through its human-first, tech-augmented model that prioritizes in-home delivery over facility-based care:
ConcertoCare rides the value-based care wave in aging U.S. healthcare, where Medicare growth (projected 20% senior population rise by 2030) demands cost-effective alternatives to high-utilization ERs and hospitals.[1][2] Its timing aligns with post-COVID shifts to in-home and virtual care, accelerated by telehealth expansions and social determinants focus under CMS reforms, enabling risk-bearing contracts that reward outcomes over volume.[3][4][6] Market forces like payer pressures for 20-50% cost reductions in complex populations favor its model, influencing the ecosystem by proving tech-human hybrids scale (e.g., via Deerfield backing) and inspiring competitors in population health tech.[2][5] The 2023 PACE divestiture to InnovAge highlights strategic pivots to core strengths, amplifying home-based innovations amid $4T+ U.S. healthcare spend.[2]
ConcertoCare is poised for nationwide scaling, leveraging Patient3D enhancements and equity funding to penetrate more states, targeting deeper Medicare Advantage penetration amid rising dual-eligible seniors.[1][2] Trends like AI-driven predictive care, expanded remote monitoring mandates, and social care reimbursements will propel growth, potentially doubling revenue as outcomes data attracts payers.[1][4] Its influence may evolve by setting standards for tech-integrated, home-first models, reducing system-wide costs—echoing its founding mission to orchestrate care that keeps vulnerable patients independent and thriving at home.[3][6]
ConcertoCare has raised $140.0M in total across 2 funding rounds.
ConcertoCare's investors include AirAngels, Arkitekt Ventures, Benchmark, Climate Capital, Deerfield Management, Earthshot Ventures, Endeavor8, Ensemble VC, Foresite Capital, Friedom Partners, Harrison Metal, Index Ventures.
ConcertoCare has raised $140.0M across 2 funding rounds. Most recently, it raised $110.0M Series B in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $110.0M Series B | AirAngels, Arkitekt Ventures, Benchmark, Climate Capital, Deerfield Management, Earthshot Ventures, Endeavor8, Ensemble VC, Foresite Capital, Friedom Partners, Harrison Metal, Index Ventures, Kapor Capital, Ligature, LombardStreet Ventures, Obvious Ventures, S2G Ventures, Sequoia Capital, Torch Capital, Vast Ventures, Max Ventilla | |
| Oct 1, 2016 | $30.0M Venture Round | Deerfield Management |